ABS-201 for improving hair growth in healthy adults and people with androgenetic alopecia
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ABS-201 in Adult Participants With and Without Androgenetic Alopecia
Run by Absci Pty Ltd. · NCT07317544 · Data updated 2026-11-12
This trial will test whether ABS-201 is safe and helps hair grow in healthy adults and in men and women with androgenetic alopecia.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 227 (estimated) |
| Sponsor | Absci Pty Ltd. Industry-sponsored |
| Locations | 5 sites (Sydney, New South Wales and 4 other locations) |
| Status | Recruiting |
| Started | December 3, 2025 |
| Main results expected | July 2028 |
| Study ends | July 2028 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT07317544 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults who are generally healthy, meet the Norwood-Hamilton III–V pattern for AGA (for the patient cohorts), have BMI 18–32 and weight >60 kg, can give informed consent, and can attend clinic visits and avoid pregnancy during the study.
✕Probably not a fit
People with other forms of hair loss (such as alopecia areata or scarring alopecia), significant medical problems, pregnant or breastfeeding individuals, or those outside the specified BMI/weight or pattern-stage criteria are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
ABS-201 is being tested in a Phase 1/2, randomized, placebo-controlled design with single ascending IV doses and multiple ascending subcutaneous doses. The trial begins with healthy volunteers to establish safety and tolerability and then enrolls participants with androgenetic alopecia to explore effects on hair growth. Participants receive either ABS-201 or placebo and attend scheduled clinic visits for safety labs, ECGs, and scalp assessments over roughly one year. Standard scalp imaging and hair measurements will be used alongside clinical safety monitoring to track responses and adverse events.
Why it matters
Potential benefit: If successful, ABS-201 could become a new systemic option to promote hair regrowth for people with androgenetic alopecia.
How similar studies have gone: This is an early-stage, novel therapy for AGA; established treatments remain topical minoxidil and oral finasteride, and comparable systemic biologic approaches have shown limited and mixed success so far.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (Major): * Participants must be overtly healthy, as determined by medical evaluation, which includes a review of medical and surgical history, physical examination, and a 12-lead ECG. * Must have normal ranges for hematology, clinical chemistry, coagulation tests, and urine analysis parameters * Participants, male and female, must be willing to avoid pregnancy for the duration of the trial. * Participants must be capable of giving signed informed consent * Participants must have no signs or symptoms of active or latent tuberculosis (TB), Additional Inclusion criteria for patients with AGA: * Diagnosis of AGA with a Norwood-Hamilton Scale III vertex to V pattern. * Willing to clip target hair area for analysis and avoid scalp pigmentation products. * Willingness to maintain approximately the same hair length at each study visit Exclusion Criteria (Major): * History or presence of cancer, except for basal cell carcinoma or cervical dysplasia successfully treated with no recurrence for ≥90 days before screening. * History of liver disease, Gilbert's syndrome, or abnormal liver function tests (e.g., ALT, AST, or bilirubin \> ULN) at screening * Systolic blood pressure ≤90 or ≥140 mmHg, diastolic BP ≤40 or ≥90 mmHg, pulse rate \<40 or \>100 bpm * Positive test for HIV, hepatitis B (HBV), or hepatitis C (HCV). * Recent blood donation * Any clinically significant psychiatric disorder * Pregnant or breastfeeding females or those planning pregnancy during the study. * History of postpartum depression, perimenopausal mood instability, or estrogen withdrawal syndrome Additional Exclusion criteria for participants with AGA undergoing hair assessments: • Prior use of hair loss treatments: 1. Topical minoxidil within 3 months before screening. 2. Oral minoxidil other hair growth stimulators within 6 months before screening. 3. Finasteride within 6 months before screening 4. Dutasteride within 12 months before screening. * Use of GLP-1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, or similar agents) within 3 months prior to screening * History of hair transplantation or other major scalp procedures or planned procedures during the study. * Use of hair extensions, wigs, hairpieces, weaves, or any other artificial hair enhancement methods within 30 days prior to screening and throughout the study. * History of clinically significant dermatologic disease of the scalp that could interfere with hair assessments or target area imaging
Where it's running
-
Momentum Darlinghurst
Sydney, New South Wales, Australia Recruiting -
Nucleus Network Brisbane
Brisbane, Queensland, Australia Recruiting -
Sinclair Dermatology
Melbourne, Victoria, Australia Recruiting -
Nucleus Network
Melbourne, Victoria, Australia Recruiting -
DermCo Pty Ltd
South Perth, Western Australia, Australia Recruiting
Study contacts
- Study coordinator: Clinical Trial Information Desk
- Email: clinicaltrialinfo@absci.com
- Phone: +1 360.949.1041
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improved method to measure bone blood flow with total-body PET/CT in healthy adults
This study tests whether a whole-body PET/CT scan using a safe radioactive tracer can measure bone blood flow in healthy volunteers aged over 50.
-
Exosome therapy for male pattern baldness
This trial tests whether injecting hUCMSC-derived exosomes into the scalp can promote hair regrowth in men with androgenetic alopecia, compared with a placebo.
-
Multi-omics view of androgenetic alopecia in scalp tissue
This study tests a multi-omics approach to understand hair follicle biology in men with androgenetic alopecia by comparing affected and healthy scalp tissue.
-
VENEZE peptide hair serum versus 2% topical minoxidil for androgenetic alopecia
This trial tests if VENEZE peptide hair serum helps adults with androgenetic alopecia grow thicker, denser hair compared with 2% topical minoxidil.
-
ORN252 in healthy adults
This will test whether ORN252 is safe and well tolerated in healthy adult men and women.
-
Topical Lactobacillus reuteri for hair loss due to androgenetic alopecia
This trial will test whether applying a topical Lactobacillus reuteri solution can increase hair count and improve hair quality in adults (18–60) with androgenetic alopecia over 12 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.